Anticoagulant use for atrial fibrillation in the elderly

Journal of the American Geriatrics Society

Volumn 52, Issue 7, 2004, Pages 1151-1156

  Brophy, Mary T ^a,b,c   Snyder, Kerri E ^a,e   Gaehde, Stephan ^b,c   Ives, Charlene ^b   Gagnon, David ^a,d   Fiore, Louis D ^a,b,c,d  

^a Massachusetts Veterans Epidemiology Research and Information Center   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BOSTON UNIVERSITY   (United States)

^e VA BOSTON HEALTHCARE SYSTEM   (United States)

Author keywords

Anticoagulation; Atrial fibrillation; Geriatrics; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; DECISION MAKING; DIABETES MELLITUS; DRUG CONTRAINDICATION; DRUG USE; ELECTROCARDIOGRAM; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; RISK FACTOR; SENESCENCE; STROKE;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; COMORBIDITY; FEMALE; HUMANS; MALE; RETROSPECTIVE STUDIES; RISK FACTORS; UNITED STATES; VETERANS; WARFARIN;

EID: 3042712422     PISSN: 00028614     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2004.52314.x     Document Type: Article

References (30)

1. Feinberg WM, Blackshear JL, Laupacis A et al. The prevalence of atrial fibrillation. Analysis and implications. Arch Intern Med 1995;155:469-473.
2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. Arch Intern Med 1987;147:1561.
3. Wolf PA, Dawber TR, Thomas HE Jr et al. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: The Framingham Study. Neurology 1978;28:973-977.
4. Albers G, Dalen J, Laupacis A et al. Antithrombotic therapy in atrial fibrillation. Chest 2001;119:194S-206S.
5. Stroke Prevention in Atrial Fibrillation Trial: Final Results. Circulation 1991;84:527-539.
6. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J Med 1990;323:1505-1511.
7. Ezekowitz M, Bridgers S, James K et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992;327:1406-1412.
8. Peterson P, Boysen G, Godfredsen J et al. Placebo-controlled randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: The Copenhagen AFASAK Study. Lancet 1989;1:175.
9. Connolly SJ, Laupacis A, Gent M et al. Canadian atrial fibrillation anticoagulation (CAFA) study. J Am Coll Cardiol 1991;18:349.
10. Risk factors for stroke and efficacy of anti-thrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled studies. Arch Intern Med 1994;154:1449-1457.
11. Ceresne L, Upshur R. Atrial fibrillation in a primary care practice. Prevalence and management. BMC Fam Pract 2002;3:11.
12. Go A, Hylek E, Borowsky L et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: The Anticoagulation and Risk Factor in Atrial Fibrillation (ATRIA) Study. Ann Intern Med 1999;131:927-934.
13. Bradley B, Perdue K, Tisdel K et al. Frequency of anticoagulation for atrial fibrillation and reasons for its non-use at a veterans affairs medical center. Am J Cardiol 2000;85:568-572.
14. Bungard TJ, Ghali WA, McAlister FA et al. Physician's perceptions of the benefits and risk of warfarin for patients with nonvalvular atrial fibrillation. Can Med Assoc J 2001;165:301-302.
15. Launbjerg J, Egeblad H, Heaf J et al. Bleeding complications to oral anticoagulant therapy: Multivariate analysis of 1,010 treatment years in 551 outpatients. J Intern Med 1991;229:351-355.
16. Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: Incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989;87:144-152.
17. Van den Meer FJ, Rosendaal FR, Vandenbroucke JP et al. Bleeding complications in oral anticoagulant therapy. Arch Intern Med 1993;153:1557.
18. Petitti D, Strom BL, Melmon KL. Duration of warfarin anticoagulation therapy and the probabilities or recurrent thromboembolism and hemorrhage. Am J Med 1986;81:255-259.
19. Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. Arch Intern Med 1996;156:409-416.
20. Chang HJ, Bell JR, Deroo DB et al. Physician variation in anticoagulating patients with atrial fibrillation. Arch Intern Med 1990;150:81-84.
21. Kumer M, Nixon G, Silverstone F. Physicians attitudes toward oral anticoagulants and antiplatelet agents for stroke prevention in elderly patients with atrial fibrillation. Arch Intern Med 1991;151:1950.
22. McCrory DC, Matchar DB, Samsa G et al. Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly. Arch Intern Med 1995;155:277-281.
23. Gage BF, Waterman AD, Shannon W et al. Validation of clinical classification schemes for predicting stroke: Results from the registry of atrial fibrillation. JAMA 2001;285:2864-2870.
24. Devereaux PJ, Anderson DR, Gardner MJ et al. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: Observational study. BMJ 2001;323:1218-1222.
25. Fihn SD, Callahan CM, Martin DC et al. The risk for and severity of bleeding complications in elderly patients treated with warfarin. Ann Intern Med 1996;124:970-979.
26. Protheroe J, Fahey T, Montgomery AA et al. The impact of patients' preferences on the treatment of atrial fibrillation: Observational study of patient based decision analysis. BMJ 2000;320:1380-1384.
27. Howitt A, Armstrong D. Implementing evidence based medicine in general practice: audit and quality study of antithrombotic treatment for atrial fibrillation. BMJ 1999;318:1324-1327.
28. Lundstrom T, Ryden L. Hemorrhagic and thromboembolic complications in patients with atrial fibrillation on anticoagulant prophylaxis. J Intern Med 1989;225:137-142.
29. Landefeld S, Cook F, Flatley M et al. Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med 1987;82:703-771.
30. Beyth RJ, Landefeld CS. Anticoagulants in older patients: a safety perspective. Drugs Aging 1995;6:45-54.